Journal Article10.1007/S00280-014-2378-Z
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old.
Milena Gusella,A. Bononi,Yasmina Modena,Laura Bertolaso,Paola Franceschetti,Daniela Menon,E. Pezzolo,Carmen Barile,Giorgio Crepaldi,C Bolzonella,Alessandro Inno,Roberto Padrini,Felice Pasini +12 more
13
TL;DR: Increased systemic drug exposure over subsequent cycles; association of age with increased drug exposure, reduced DNA repair capability and worse skin toxicity; and a relation between monocyte count and drug clearance are shown.
read more
Abstract: Purpose
Pegylated liposomal doxorubicin (PLD) is often used in elderly people, due to its improved tolerability. However, clinical and pharmacological data in the subset of patients over 70 are scanty.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
TL;DR: The unique disposition characteristics of nanoparticles are reviewed, how PBPK modeling takes into account the unique disposition properties of nanoparticle properties is assessed, and the applications and challenges of P BPK modeling in characterizing and predicting the disposition and biological effects of nanop particles are commented on.
144
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology
TL;DR: This review aims to cover the main causes for erratic pharmacokinetics observed with most nanoparticles, especially liposomes used in oncology and calls for the development of comprehensive distribution studies and state-of-the-art modeling support to better understand and anticipate nanoparticle pharmacokinetic in onCology.
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.
Maximilian Richter,Roma Yumul,Hongjie Wang,Kamola Saydaminova,Martin Ho,Drew May,Audrey Baldessari,Michael Gough,Charles W. Drescher,Nicole Urban,Steve R. Roffler,Chloe Zubieta,Darrick Carter,Pascal Fender,André Lieber +14 more
TL;DR: Data is provided toward the clinical translation of an affinity-enhanced version of JO-1, which is called JO-4, in combination with PEGylated liposomal doxorubicin (PLD)/Doxil for ovarian cancer therapy and X-ray crystallography data is presented suggesting a structural basis for the higher affinity ofJO-4 to DSG2.
25
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents
TL;DR: An overview of factors that affect the pharmacologic profiles observed in CMA-formulated chemotherapy, primarily in liposomal formulations, that are currently in preclinical or early clinical development are provided.
17
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters
Zahra Ajgal,Nicolas Chapuis,George Emile,George Emile,Anatole Cessot,Jean Marie Tigaud,Olivier Huillard,Pascaline Boudou-Rouquette,Michaela Fontenay,F. Goldwasser,Jérôme Alexandre +10 more
TL;DR: Contrary to most acute toxicities, PPE occurred more frequently after several cycles, suggesting a PLD body accumulation through repeated cycles.
8
References
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
TL;DR: An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.
The Comet Assay for DNA Damage and Repair: Principles, Applications, and Limitations
TL;DR: The comet assay (single-cell gel electrophoresis) is a simple method for measuring deoxyribonucleic acid (DNA) strand breaks in eukaryotic cells that has applications in testing novel chemicals for genotoxicity, monitoring environmental contamination with genotoxins, human biomonitoring and molecular epidemiology, and fundamental research in DNA damage and repair.
2.9K
Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
TL;DR: The ability of pegylated liposomes to extravasate through the leaky vasculature of tumours, as well as their extended circulation time, results in enhanced delivery of liposomal drug and/or radiotracers to the tumour site in cancer patients.
1.5K
Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review.
Marije E. Hamaker,Judith M Jonker,Sophia E. de Rooij,Alinda G. Vos,Carolien H. Smorenburg,Barbara C. van Munster,Barbara C. van Munster +6 more
TL;DR: It might be beneficial for all elderly patients with cancer to receive a complete geriatric assessment, since available frailty screening methods have insufficient discriminative power to select patients for further assessment.
609
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Olga Lyass,Beatrice Uziely,Rami Ben-Yosef,Dinah Tzemach,Norman I. Heshing,Michal Lotem,George Brufman,Alberto Gabizon +7 more
TL;DR: Doxil (ALZA Corp., Mountain View, CA) is a formulation of doxorubicin in polyethylene‐glycol coated liposomes with a prolonged circulation time and unique toxicity profile.
400